Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 17/20 | 0.38 |
| ▸ | JAK1 | P23458 | 17/20 | 0.38 |
| ▸ | TYK2 | P29597 | 4/20 | 0.38 |
| ▸ | JAK3 | P52333 | 4/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.38 |
| ▸ | F11 | P03951 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17271442 | 0.86 | F11 (0.34) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL17271435 | 0.82 | MEN1 (0.35) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL17282255 | 0.81 | P2RX3 (0.39) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL29648500 | 0.80 | JAK2 (0.37) | JAK2JAK1TYK2JAK3F11 | |
| SCHEMBL17271462 | 0.79 | F11 (0.35) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL28695876 | 0.79 | JAK2 (0.56) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL29488743 | 0.79 | JAK2 (0.56) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL28695877 | 0.78 | JAK2 (0.55) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL29488719 | 0.78 | JAK2 (0.55) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL11027100 | 0.78 | JAK2 (0.39) | JAK2JAK1TYK2JAK3IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3145929-B1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS WHICH ARE JAK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-01-13 | — | — | EP | disclosed |
| US-20190322661-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322661-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, FLT3 | JAK2 2/4885JAK1 4/4885TYK2 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.